Nakamura, H.; Watanabe, M.; Takada, K.; Sato, T.; Hikage, F.; Umetsu, A.; Muramatsu, J.; Furuhashi, M.; Ohguro, H.
Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel. Biomedicines 2024, 12, 1011.
https://doi.org/10.3390/biomedicines12051011
AMA Style
Nakamura H, Watanabe M, Takada K, Sato T, Hikage F, Umetsu A, Muramatsu J, Furuhashi M, Ohguro H.
Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel. Biomedicines. 2024; 12(5):1011.
https://doi.org/10.3390/biomedicines12051011
Chicago/Turabian Style
Nakamura, Hajime, Megumi Watanabe, Kohichi Takada, Tatsuya Sato, Fumihito Hikage, Araya Umetsu, Joji Muramatsu, Masato Furuhashi, and Hiroshi Ohguro.
2024. "Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel" Biomedicines 12, no. 5: 1011.
https://doi.org/10.3390/biomedicines12051011
APA Style
Nakamura, H., Watanabe, M., Takada, K., Sato, T., Hikage, F., Umetsu, A., Muramatsu, J., Furuhashi, M., & Ohguro, H.
(2024). Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel. Biomedicines, 12(5), 1011.
https://doi.org/10.3390/biomedicines12051011
